Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Open access

Abstract

Expression of B7-H1, a costimulating glycoprotein in the B7 family, is normally restricted to macrophage-lineage cells, providing a potential costimulatory signal source for regulation of T cell activation. In contrast, aberrant expression of B7-H1 by tumor cells has been implicated in impairment of T cell function and survival, resulting in defective host antitumoral immunity. The relationship between tumor-associated B7-H1 and clinical cancer progression is unknown. Herein, we report B7-H1 expression by both renal cell carcinoma (RCC) tumors of the kidney and RCC tumor-infiltrating lymphocytes. In addition, our analysis of 196 clinical specimens reveals that patients harboring high intratumoral expression levels of B7-H1, contributed by tumor cells alone, lymphocytes alone, or tumor and/or lymphocytes combined, exhibit aggressive tumors and are at markedly increased risk of death from RCC. In fact, patients with high tumor and/or lymphocyte B7-H1 levels are 4.5 times more likely to die from their cancer than patients exhibiting low levels of B7-H1 expression (risk ratio 4.53; 95% confidence interval 1.94–10.56; P < 0.001.) Thus, our study suggests a previously undescribed mechanism whereby RCC may impair host immunity to foster tumor progression. B7-H1 may prove useful as a prognostic variable for RCC patients both pre- and posttreatment. In addition, B7-H1 may represent a promising target to facilitate more favorable responses in patients who require immunotherapy for treatment of advanced RCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0406351101

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 11

  1. Strome, S.-E., Dong, H., Tamura, H., Voss, S.-G., Flies, D.-B., Tamada, K., Salomao, D., Cheville, J.-C, Hirano, F., Lin, W., et al. (2003) Cancer Res. 63, 6501–6505.14559843
  2. Graham, S., Babayan, R.-K., Lamm, D.-L., Sawczuk, I., Ross, S.-D., Lavin, P.-T., Osband, M.-E. & Krane, R.-J. (1993) Semin. Urol. 11, 27–34.8465126
  3. Krejci, K.-G., Markiewicz, M.-A. & Kwon, E.-D. (2003) J. Urol. 171, 870–876.
  4. Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H. & Ohtani, H. (2001) Cancer Res. 61, 5132–5136.11431351
  5. Wintterle, S., Schreiner, B., Mitsdoerffer, M., Schneider, D., Chen, L., Meyermann, R., Weller, M. & Wiendl, H. (2003) Cancer Res. 63, 7462–7467.14612546
  6. Uzzo, R.-G., Rayman, P., Kolenko, V., Clark, P.-E., Bloom, T., Ward, A.-M., Molto, L., Tannenbaum, C., Worford, L.-J, Bukowski, R.-M., et al. (1999) Clin. Cancer Res. 5, 1219–1229.10353760
  7. Alexander, J.-P., Kudoh, S., Melsop, K.-A., Hamilton, T.-A., Edinger, M.-G., Tubbs, R.-R., Sica, D., Tuason, L., Klein, E., Bukowski, R., et al. (1993) Cancer. Res. 53, 1380–1387.8443817
  8. Li, X., Liu, J., Park, J.-K., Hamilton, T.-A., Rayman, P., Klein, E., Edinger, M., Tubbs, R., Bukowski, R. & Finke, J. (1994) Cancer Res. 54, 5424–5429.7923175
  9. Kudoh, S., Redovan, C., Rayman, P., Edinger, M., Tubbs, R.-R., Novick, A., Finke, J.-H. & Bukowski, R.-M. (1997) J. Immunol. 20, 479–487.
  10. Motzer, R.-J. (2003) Crit. Rev. Oncol. Hematol. 46S, s33–s39.
  11. Shimazui, T., Oosterwijk, E., Akaza, H., Bringuier, P., Ruijter, E., van Berkel, H., Wakka, J.-O., van Bokhoven, A., Debruyne, F.-M. & Schalken, J.-A. (1998) Clin. Cancer Res. 4, 2419–2424.9796973

Cited by

See all 796

Metadata

Authors
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D.
Affiliations
Mayo Clinic (US)
Venue
Proceedings of the National Academy of Sciences
Published
2004-11-29
Volume
101
Issue
49
Pages
17174-17179
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4230861071
Cited by
776
References
48
Citations by year
2026: 7 · 2025: 14 · 2024: 15 · 2023: 29 · 2022: 32 · 2021: 42 · 2020: 51 · 2019: 60 · 2018: 57 · 2017: 76 · 2016: 65 · 2015: 69 · 2014: 57 · 2013: 29 · 2012: 28
FWCI
9.14
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
PD-L1, renal cell carcinoma, tumor-infiltrating lymphocytes, tumor progression, prognostic factors, tumor immune evasion, T cell costimulation, immunotherapy targets, cancer mortality
MeSH terms
Carcinoma, Renal Cell, Follow-Up Studies, Humans, Immunity, Immunohistochemistry, Membrane Glycoproteins, Neoplasm Proteins, Peptides, Prognosis, Antigens, CD, Odds Ratio, Survival Analysis, Lymphocytes, Tumor-Infiltrating, B7-1 Antigen, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. https://app.cochat.ai/papers/10.1073/pnas.0406351101
The paper
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., Zincke, H., Blute, M. L., Strome, S. E., Leibovich, B. C., & Kwon, E. D. (2004). Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0406351101

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.